Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia Patients

NCT06923891 is registered in ClinicalTrials.gov with Vanguard Research Group as lead sponsor.

NCT NCT06923891
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06923891 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia Patients
Lead sponsor
Vanguard Research Group
Phase
Phase 4
Overall status
Not yet recruiting
Start date
April 16, 2025
Completion date
November 30, 2026
Enrollment
172 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia